# Surv Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surv-biopharma

- Industry: Biotechnology
- Headquarters: Kagoshima-shi, Japan
- Website: www.survbiopharma.co.jp
- Total disclosed funding: $14M
- Latest round: Series B (Dec 23, 2025)
- Investors on record: 13

## About

Established in 2022 and based in Kagoshima, Japan, Surv Biopharma Inc. is a pharmaceutical development and support company that engages in clinical applications, diagnostics, consulting, manufacturing, and sales support services. As of January 2023, Kenichiro Obasu serves as the CEO of the company. In November 2025, Surv Biopharma Inc. raised JPY 1.5 billion series B funding led by new investor Keio Innovation Initiative, with participation from other new investors QB Capital, Fujita Innovation Capital, Nippon Venture Capital and Higin Capital. Returning investors Kagoshima Development and Daiwa Corporate Investment also participated in the round.

The company provides a drug discovery technology platform, which is a replicating adenovirus with multifactorial control that affects only cancer cells and not normal cells (m-CRA). The company is working on a practical application of virotherapy based on the developed oncolytic virus. Surv Biopharma's pipeline of oncolytic viruses includes the Surv.m-CRA series, which target survivin, a protein that is only found in cancer cells. Surv Biopharma Inc. revenue by developing and licensing innovative oncolytic virus therapies for cancer treatment, supported by strategic partnerships and clinical trial collaborations.

The company plans to use the November 2025 funding to expedite non-clinical and international clinical development.

## Funding rounds

- Series B, Dec 23, 2025, $4.3M — Sagin Capital & Consulting, Oita Venture Capital, Kyoto University Innovation Capital, FFG Venture Business Partners, Fukuoka Jisho Co., Ltd., Toho Holdings
- Series B, Nov 11, 2025, $9.8M — Daiwa Corporate Investment, Nippon Venture Capital, Keio Innovation Initiative, Higin Capital, Kagoshima Development, QB Capital, Fujita Innovation Capital

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series B
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series B
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series B
- Higin Capital (https://capitalatlas.ai/funds/higin-capital) — Series B
- Kagoshima Development — Series B
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series B
- Fujita Innovation Capital (https://capitalatlas.ai/funds/fujita-innovation-capital) — Series B
- Sagin Capital & Consulting (https://capitalatlas.ai/funds/sagin-capital-consulting) — Series B
- Oita Venture Capital (https://capitalatlas.ai/funds/oita-venture-capital) — Series B
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series B
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series B
- Fukuoka Jisho Co., Ltd. — Series B
- Toho Holdings — Series B